Drug development solution company Altasciences announced on Thursday that it has entered into a strategic partnership with biosimulation software specialist Certara Inc (NASDAQ:CERT) to accelerate early-phase development programs.

This collaboration targets key challenges in drug development, where fewer than half of preclinical candidates advance to first-in-human trials due to issues including toxicity, pharmacokinetics, efficacy, and translational gaps between animal and human data.

By integrating Certara's biosimulation technology and drug development services with Altasciences' Acceleration Platform, the partnership aims to improve study design, optimide dosing strategies, and support earlier proof-of-mechanism decisions. The approach embeds modelling insights and digital workflows across non-clinical, clinical, bioanalytical, and manufacturing processes to improve program integration and decision-making confidence.

The companies said that the initiative aligns with evolving US Food and Drug Administration (FDA) expectations for more adaptive and data-driven development frameworks.

Altasciences and Certara will focus on a model-first, resource-efficient development approach intended to accelerate proof-of-concept timelines for biotechnology and pharmaceutical clients globally.